Nippon India Pharma Fund vs Tata India Pharma & Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
Nippon India Pharma Fund is a Sectoral fund and Tata India Pharma & Healthcare Fund is a Thematic fund. In the 3 years to 30-10-2026, Nippon India Pharma Fund (Direct) returned 18.6% a year and Tata India Pharma & Healthcare Fund (Direct) returned 19.3% a year. Nippon India Pharma Fund charges 0.99% a year and Tata India Pharma & Healthcare Fund 1.10% (Direct plans). Their portfolios overlap 52.2%: they hold 22 of the same securities.
Nippon India Pharma Fund
Sectoral
- 3 year return
- 18.6%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
Tata India Pharma & Healthcare Fund
Thematic
- 3 year return
- 19.3%
- Expense ratio
- 1.10%
- NAV
- ₹37.77
Which is better, Nippon India Pharma or Tata India Pharma & Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Tata India Pharma & Healthcare returned more over 5 years: 14.9% a year against 14.2%.
- Tata India Pharma & Healthcare returned more over 3 years: 19.3% a year against 18.6%.
- Nippon India Pharma costs less: 0.99% a year against 1.10% (Direct plans).
- Nippon India Pharma swung less over 3 years: a standard deviation of 13.0% a year against 13.2%.
- Tata India Pharma & Healthcare fell less in its worst fall since 29-12-2015: −19.8% against −21.2%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹1,511 Cr.
- Their portfolios overlap 52.2%: 22 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Nippon India Pharma Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Fund house | Nippon India Mutual Fund | Tata Mutual Fund |
| Category | Sectoral | Thematic |
| AUM | ₹9,166 Cr (30-09-2026) | ₹1,511 Cr (30-09-2026) |
| NAV | ₹625.46 (Direct) | ₹37.77 (Direct) |
| Expense ratio (Direct) | 0.99% | 1.10% |
| Expense ratio (Regular) | 1.85% | 2.42% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 05-06-2004 | 28-12-2015 |
| Minimum investment | ₹5,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Sailesh Raj Bhan | Rajat Srivastava |
| Exit load | Exit load of 1% if redeemed within 1 month. | 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment. |
Nippon India Pharma vs Tata India Pharma & Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Tata India Pharma & Healthcare Fund (Direct) | −1.40% | −5.00% | +6.91% | +4.28% | +19.28% | +14.93% | +14.64% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | +13.76% |
Category average: the average of the 20 Sectoral funds and the 235 Thematic funds, same plan type.
Nippon India Pharma vs Tata India Pharma & Healthcare: Year-wise Returns
| Year | Nippon India PharmaNippon India Pharma | Tata India Pharma & HealthcareTata India Pharma & Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +9.76% | +6.77% | +15.08% |
| 2025 | −2.46% | −3.47% | −2.72% |
| 2024 | +35.26% | +42.48% | +44.30% |
| 2023 | +40.36% | +38.59% | +37.97% |
| 2022 | −9.06% | −6.64% | −11.50% |
| 2021 | +25.12% | +20.88% | +21.54% |
Nippon India Pharma vs Tata India Pharma & Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 3-year holding period, 1,930 of them, one for each trading day from 31-12-2018 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Nippon India Pharma Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
to
Aug 2019Dec 2017
to
Dec 2020Apr 2019
to
Apr 2022Aug 2020
to
Aug 2023Dec 2021
to
Dec 2024Mar 2023
to
Mar 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma | 1.2 | 10.2 | 4.9 | 3.4 | 24.6 | 35.4 | 20.3 | 18.8% | 20.7% | −1.3% | 32.2% | 75% |
| Tata India Pharma & Healthcare | 9.1 | 5.7 | 2.8 | 3.1 | 21.3 | 38.2 | 19.6 | 18.2% | 21.2% | −3.4% | 30.5% | 83% |
| BSE Healthcare TRI | 16.5 | 1.5 | 2.2 | 14.0 | 23.3 | 33.7 | 8.8 | 15.4% | 19.0% | −9.9% | 28.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 29-12-2015. Past returns do not promise future returns.
Nippon India Pharma vs Tata India Pharma & Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-12-2015 to 30-10-2026: 131 instalments, ₹13,10,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹13,10,000 | ₹35,83,039 | ₹22,73,039 | 17.4% |
| Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct) | ₹13,10,000 | ₹34,72,173 | ₹21,62,173 | 16.9% |
Nippon India PharmaNippon India Pharma Fund (Direct)
Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Nippon India Pharma vs Tata India Pharma & Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Nippon India Pharma Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +9.05% | +4.28% |
| Standard deviation | 12.27% | 11.99% |
| Sharpe ratio | 0.31 | -0.08 |
| Sortino ratio | 0.45 | -0.11 |
| Maximum drawdown | −9.6% (23-10-2026) | −11.0% (23-10-2026) |
| Beta | 0.87 | 0.82 |
| Alpha | −2.40% | −6.83% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Pharma Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +18.56% | +19.28% |
| Standard deviation | 12.96% | 13.21% |
| Sharpe ratio | 0.97 | 1.00 |
| Sortino ratio | 1.39 | 1.43 |
| Maximum drawdown | −14.7% (28-02-2025) | −16.8% (28-02-2025) |
| Beta | 0.88 | 0.89 |
| Alpha | −2.50% | −1.91% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Pharma Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +14.19% | +14.93% |
| Standard deviation | 12.88% | 12.92% |
| Sharpe ratio | 0.65 | 0.71 |
| Sortino ratio | 0.93 | 1.01 |
| Maximum drawdown | −18.7% (17-06-2022) | −16.8% (28-02-2025) |
| Beta | 0.89 | 0.89 |
| Alpha | −0.35% | +0.41% |
From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Pharma Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +17.18% | +13.01% |
| Standard deviation | 15.19% | 15.08% |
| Sharpe ratio | 0.73 | 0.50 |
| Sortino ratio | 1.06 | 0.72 |
| Maximum drawdown | −24.0% (29-05-2017) | −19.8% (21-08-2017) |
| Beta | 0.85 | 0.87 |
| Alpha | +3.72% | +2.53% |
From daily NAVs, 02-01-2013 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Nippon India Pharma Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund (Direct) | −21.2% | 19-02-2020 | 23-03-2020 | 09-04-2020 | 17 days | −4.3% |
| Tata India Pharma & Healthcare Fund (Direct) | −19.8% | 01-02-2016 | 21-08-2017 | 31-08-2018 | 12 months | −6.0% |
| BSE Healthcare TRI | −33.2% | 29-12-2015 | 23-03-2020 | 22-06-2020 | 3 months | −3.8% |
From daily values since 29-12-2015, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Pharma Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Pharma Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 5-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Pharma Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Nippon India Pharma Fund (Direct) | 93% | 77% | 4.57% |
| Tata India Pharma & Healthcare Fund (Direct) | 92% | 79% | 4.99% |
From month-end values since 29-12-2015. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Nippon India Pharma vs Tata India Pharma & Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Nippon India Pharma Fund, September 2026; Tata India Pharma & Healthcare Fund, September 2026
Holdings in common
- Overlap
- 52.2%
- Held by both
- 22
- Only in Nippon India Pharma
- 14
- Only in Tata India Pharma & Healthcare
- 19
| Security | % of Nippon India Pharma | % of Tata India Pharma & Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.71% | 7.99% |
| Divi's Laboratories Limited | 7.10% | 5.68% |
| Dr. Reddy's Laboratories Limited | 5.45% | 4.65% |
| Apollo Hospitals Enterprise Limited | 4.89% | 4.36% |
| Cipla Limited | 6.01% | 4.22% |
| Lupin Limited | 6.17% | 3.14% |
| Max Healthcare Institute Limited | 2.70% | 3.71% |
| Sai Life Sciences Limited | 3.92% | 2.60% |
| Abbott India Limited | 2.32% | 5.94% |
| Alkem Laboratories Limited | 1.82% | 2.36% |
| Dr. Lal Path Labs Limited | 2.17% | 1.76% |
| Ajanta Pharma Limited | 3.61% | 1.63% |
| Syngene International Limited | 1.40% | 2.85% |
| Pfizer Limited | 1.35% | 2.50% |
| Anthem Biosciences Limited | 1.19% | 2.57% |
| Fortis Healthcare Limited | 1.13% | 1.95% |
| IPCA Laboratories Limited | 2.87% | 0.91% |
| Mankind Pharma Limited | 4.38% | 0.77% |
| GlaxoSmithKline Pharmaceuticals Limited | 3.11% | 0.76% |
| Biocon Limited | 1.01% | 0.69% |
| Sanofi Consumer Healthcare India Limited | 0.89% | 0.57% |
| Molbio Diagnostics Limited | 0.54% | 0.54% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 52.2% means 52.2% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Vijaya Diagnostic Centre Limited | 2.62% |
| MedPlus Health Services Limited | 2.53% |
| Gland Pharma Limited | 2.53% |
| Piramal Pharma Limited | 2.24% |
| Thyrocare Technologies Limited | 2.24% |
Largest holdings only in Tata India Pharma & Healthcare Fund
| Security | % of fund |
|---|---|
| HEALTHCARE GLOBAL ENTERPRISES LTD | 5.92% |
| RAINBOW CHILDRENS MEDICARE LTD | 4.30% |
| TORRENT PHARMACEUTICALS LTD | 3.76% |
| BAYER CROPSCIENCE LTD | 2.96% |
| PROCTER & GAMBLE HEALTH LTD | 2.75% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Nippon India Pharma | Tata India Pharma & Healthcare |
|---|---|---|
| Equity | 97.3% | 99.7% |
| Debt | 0.0% | 0.0% |
| Cash and others | 2.7% | 0.3% |
Market cap of stocks
| Market cap | Nippon India Pharma | Tata India Pharma & Healthcare |
|---|---|---|
| Large Cap | 29.7% | 26.0% |
| Mid Cap | 39.0% | 33.9% |
| Small Cap | 28.0% | 37.0% |
| Not on AMFI's list | 0.5% | 2.9% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Nippon India Pharma | Tata India Pharma & Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.0% | 60.6% |
| Healthcare Services | 20.3% | 27.8% |
| Fertilizers & Agrochemicals | 0.0% | 6.9% |
| Chemicals & Petrochemicals | 0.0% | 2.6% |
| Retailing | 2.5% | 0.0% |
| Personal Products | 0.0% | 1.2% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Nippon India Pharma vs Tata India Pharma & Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Nippon India Pharma Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.99% | 1.10% |
| Base expense ratio (Direct) | 0.79% | 0.64% |
| Total expense ratio (Regular) | 1.85% | 2.42% |
| Base expense ratio (Regular) | 1.52% | 1.82% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Nippon India Pharma with
Compare Tata India Pharma & Healthcare with
- Tata India Pharma & Healthcare vs Nippon India Taiwan Equity
- Tata India Pharma & Healthcare vs HDFC Defence
- Tata India Pharma & Healthcare vs HDFC Pharma and Healthcare
- Tata India Pharma & Healthcare vs SBI Healthcare Opportunities
- Tata India Pharma & Healthcare vs Aditya Birla Sun Life International Equity
Nippon India Pharma Fund vs Tata India Pharma & Healthcare Fund: Frequently Asked Questions
What is the difference between Nippon India Pharma Fund and Tata India Pharma & Healthcare Fund?
Nippon India Pharma Fund is a Sectoral fund, Tata India Pharma & Healthcare Fund is a Thematic fund, run by Nippon India Mutual Fund and Tata Mutual Fund. Their portfolios overlap 52.2%. Nippon India Pharma Fund charges 0.99% a year and Tata India Pharma & Healthcare Fund 1.10%.
Which has given higher returns, Nippon India Pharma Fund or Tata India Pharma & Healthcare Fund?
Over 1 year: Nippon India Pharma Fund +9.05%, Tata India Pharma & Healthcare Fund +4.28%. Over 3 years: Nippon India Pharma Fund +18.56% a year, Tata India Pharma & Healthcare Fund +19.28% a year. Over 5 years: Nippon India Pharma Fund +14.19% a year, Tata India Pharma & Healthcare Fund +14.93% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Nippon India Pharma Fund or Tata India Pharma & Healthcare Fund?
Nippon India Pharma Fund charges less: 0.99% a year against 1.10%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Nippon India Pharma Fund and Tata India Pharma & Healthcare Fund overlap?
52.2%. They hold 22 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, DRREDDY. From each fund's latest monthly portfolio.
Which is riskier, Nippon India Pharma Fund or Tata India Pharma & Healthcare Fund?
On SEBI's riskometer, Nippon India Pharma Fund is rated Very High and Tata India Pharma & Healthcare Fund Very High. Over 3 years, the standard deviation of daily returns was 12.96% and 13.21% a year.
Which is better for SIP, Nippon India Pharma Fund or Tata India Pharma & Healthcare Fund?
Over the last 5 years, a monthly SIP of ₹10,000 from 01-10-2021 to 30-10-2026 grew to ₹9,14,295 in Nippon India Pharma Fund (XIRR 15.9% a year) and ₹9,10,986 in Tata India Pharma & Healthcare Fund (XIRR 15.8% a year). Both received 61 instalments. Past returns do not promise future returns.
Can I invest in both Nippon India Pharma Fund and Tata India Pharma & Healthcare Fund?
Yes. 52.2% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Nippon India Pharma Fund and Tata India Pharma & Healthcare Fund?
Nippon India Pharma Fund: Sailesh Raj Bhan. Tata India Pharma & Healthcare Fund: Rajat Srivastava.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.